Fiona Blanco-Kelly1, Teresa Jaijo2, Elena Aller2, Almudena Avila-Fernandez1, María Isabel López-Molina3, Ascensión Giménez4, Blanca García-Sandoval3, José M Millán5, Carmen Ayuso1. 1. Servicio de Genética, Instituto de Investigación-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain2Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain3Grupo de Investigación en Enfermedades Neurosensoriales, Instituto de Investigación Sanitaria-La Fe, Valencia, Spain. 3. Department of Ophthalmology, Instituto de Investigación-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. 4. Servicio de Genética, Instituto de Investigación-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. 5. Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain3Grupo de Investigación en Enfermedades Neurosensoriales, Instituto de Investigación Sanitaria-La Fe, Valencia, Spain5Unidad de Genética y Diagnóstico Prenatal, Hospital Universi.
Abstract
IMPORTANCE: A new statistical approach is needed to describe the clinical differences between type I and type II Usher syndrome and between the 2 most frequent mutations in the USH2A gene. OBJECTIVES: To describe the primary phenotypic characteristics and differences between type I and type II Usher syndrome and to establish a phenotype-genotype correlation for the 2 most frequent mutations in the USH2A gene. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study at a genetics department, in which clinical evaluations were performed for 433 patients (297 unrelated families) who were classified as having type I, II, III, atypical, or unclassified Usher syndrome according to their clinical history, pedigree data, results from ophthalmological studies, and audiological, neurophysiological, and vestibular test results. Molecular studies were performed for 304 patients (256 unrelated families). The Mann-Whitney U test or the χ2 test was used for calculating the differences between mean values for the analyzed parameters. MAIN OUTCOMES AND MEASURES: Age at diagnosis; age at onset of night blindness, visual field loss, visual acuity loss, and cataracts; and severity and age at diagnosis of hearing loss. RESULTS: The comparison between patients with type I Usher syndrome and those with type II Usher syndrome revealed P < .001 for most items analyzed. The most frequent mutations in the USH2A gene were the p.Glu767Serfs*21 and p.Cys759Phe mutations, with an allelic frequency of 23.2% (63 of 272 alleles) and 8.1% (22 of 272 alleles), respectively. The phenotypic analysis for patients carrying p.Cys759Phe showed P < .001 for most items analyzed when compared with patients carrying p.Glu767Serfs*21 and when compared with patients carrying other mutations in the USH2A gene. None of the p.Cys759Phe patients exhibited a severe hearing loss phenotype, and more than 60% had only mild hearing loss. Most patients carrying the p.Glu767Serfs*21 mutation (72.1%) were moderately deaf. CONCLUSIONS AND RELEVANCE: Our study presents the clinical differences between type I and type II Usher syndrome and between the 2 most frequent mutations in the USH2A gene. Detailed genotype-phenotype correlations, as presented in our study, allow for a better correlation of clinical signs with a known genotype and can improve the clinical management, genetic counseling, and risk assessment of patients with Usher syndrome because an estimated prognosis of their disease can be made.
IMPORTANCE: A new statistical approach is needed to describe the clinical differences between type I and type II Usher syndrome and between the 2 most frequent mutations in the USH2A gene. OBJECTIVES: To describe the primary phenotypic characteristics and differences between type I and type II Usher syndrome and to establish a phenotype-genotype correlation for the 2 most frequent mutations in the USH2A gene. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study at a genetics department, in which clinical evaluations were performed for 433 patients (297 unrelated families) who were classified as having type I, II, III, atypical, or unclassified Usher syndrome according to their clinical history, pedigree data, results from ophthalmological studies, and audiological, neurophysiological, and vestibular test results. Molecular studies were performed for 304 patients (256 unrelated families). The Mann-Whitney U test or the χ2 test was used for calculating the differences between mean values for the analyzed parameters. MAIN OUTCOMES AND MEASURES: Age at diagnosis; age at onset of night blindness, visual field loss, visual acuity loss, and cataracts; and severity and age at diagnosis of hearing loss. RESULTS: The comparison between patients with type I Usher syndrome and those with type II Usher syndrome revealed P < .001 for most items analyzed. The most frequent mutations in the USH2A gene were the p.Glu767Serfs*21 and p.Cys759Phe mutations, with an allelic frequency of 23.2% (63 of 272 alleles) and 8.1% (22 of 272 alleles), respectively. The phenotypic analysis for patients carrying p.Cys759Phe showed P < .001 for most items analyzed when compared with patients carrying p.Glu767Serfs*21 and when compared with patients carrying other mutations in the USH2A gene. None of the p.Cys759Phepatients exhibited a severe hearing loss phenotype, and more than 60% had only mild hearing loss. Most patients carrying the p.Glu767Serfs*21 mutation (72.1%) were moderately deaf. CONCLUSIONS AND RELEVANCE: Our study presents the clinical differences between type I and type II Usher syndrome and between the 2 most frequent mutations in the USH2A gene. Detailed genotype-phenotype correlations, as presented in our study, allow for a better correlation of clinical signs with a known genotype and can improve the clinical management, genetic counseling, and risk assessment of patients with Usher syndrome because an estimated prognosis of their disease can be made.
Authors: Heather A Stiff; Christina M Sloan-Heggen; Ashley Ko; Wanda L Pfeifer; Diana L Kolbe; Carla J Nishimura; Kathy L Frees; Kevin T Booth; Donghong Wang; Amy E Weaver; Hela Azaiez; John Kamholz; Richard J H Smith; Arlene V Drack Journal: Ophthalmic Genet Date: 2020-04-13 Impact factor: 1.803
Authors: Rosalie M Nolen; Robert B Hufnagel; Thomas B Friedman; Amy E Turriff; Carmen C Brewer; Christopher K Zalewski; Kelly A King; Talah T Wafa; Andrew J Griffith; Brian P Brooks; Wadih M Zein Journal: Ophthalmic Genet Date: 2020-05-06 Impact factor: 1.803
Authors: João Carlos Ribeiro; Bárbara Oliveiros; Paulo Pereira; Natália António; Thomas Hummel; António Paiva; Eduardo D Silva Journal: Sci Rep Date: 2016-06-22 Impact factor: 4.379
Authors: M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan Journal: Hum Genet Date: 2021-07-30 Impact factor: 4.132
Authors: Alessandro Iannaccone; Carmen C Brewer; Peiyao Cheng; Jacque L Duncan; Maureen G Maguire; Isabelle Audo; Allison R Ayala; Paul S Bernstein; Gavin M Bidelman; Janet K Cheetham; Richard L Doty; Todd A Durham; Robert B Hufnagel; Mark H Myers; Katarina Stingl; Wadih M Zein Journal: Am J Med Genet A Date: 2021-07-30 Impact factor: 2.578